MERUS NV (MRUS)

NL0011606264 - Common Stock

42.5  -0.66 (-1.53%)

Fundamental Rating

3

Overall MRUS gets a fundamental rating of 3 out of 10. We evaluated MRUS against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, MRUS is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.
In the past year MRUS has reported a negative cash flow from operations.
MRUS had negative earnings in each of the past 5 years.
MRUS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MRUS has a better Return On Assets (-28.95%) than 70.09% of its industry peers.
The Return On Equity of MRUS (-34.77%) is better than 76.22% of its industry peers.
Industry RankSector Rank
ROA -28.95%
ROE -34.77%
ROIC N/A
ROA(3y)-27.83%
ROA(5y)-28.28%
ROE(3y)-39.23%
ROE(5y)-48.66%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRUS has more shares outstanding
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 10.96 indicates that MRUS is not in any danger for bankruptcy at the moment.
MRUS's Altman-Z score of 10.96 is amongst the best of the industry. MRUS outperforms 86.85% of its industry peers.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.96
ROIC/WACCN/A
WACC7.21%

2.3 Liquidity

MRUS has a Current Ratio of 8.32. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MRUS (8.32) is better than 74.05% of its industry peers.
MRUS has a Quick Ratio of 8.32. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.32, MRUS is doing good in the industry, outperforming 74.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32

More info and screens

4

3. Growth

3.1 Past

MRUS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.72%.
MRUS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.34%.
The Revenue has been growing slightly by 2.75% on average over the past years.
EPS 1Y (TTM)-3.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-239.53%
Revenue 1Y (TTM)-21.34%
Revenue growth 3Y13.65%
Revenue growth 5Y2.75%
Sales Q2Q%6.7%

3.2 Future

Based on estimates for the next years, MRUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.67% on average per year.
MRUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.44% yearly.
EPS Next Y-28.78%
EPS Next 2Y-14.46%
EPS Next 3Y-8.32%
EPS Next 5Y13.67%
Revenue Next Year-21.79%
Revenue Next 2Y10.94%
Revenue Next 3Y20.76%
Revenue Next 5Y58.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as MRUS's earnings are expected to decrease with -8.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.46%
EPS Next 3Y-8.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (1/6/2025, 3:47:20 PM)

42.5

-0.66 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)N/A N/A
Inst Owners99.58%
Inst Owner Change0%
Ins Owners0.57%
Ins Owner Change0%
Market Cap2.91B
Analysts87.83
Price Target88.74 (108.8%)
Short Float %14.73%
Short Ratio17.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.03%
Min EPS beat(2)-62.2%
Max EPS beat(2)-3.86%
EPS beat(4)1
Avg EPS beat(4)-18.99%
Min EPS beat(4)-62.2%
Max EPS beat(4)28.31%
EPS beat(8)4
Avg EPS beat(8)-13.15%
EPS beat(12)8
Avg EPS beat(12)5.85%
EPS beat(16)9
Avg EPS beat(16)0.81%
Revenue beat(2)1
Avg Revenue beat(2)15.95%
Min Revenue beat(2)-15.38%
Max Revenue beat(2)47.28%
Revenue beat(4)1
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-20.67%
Max Revenue beat(4)47.28%
Revenue beat(8)4
Avg Revenue beat(8)2.15%
Revenue beat(12)7
Avg Revenue beat(12)3.31%
Revenue beat(16)10
Avg Revenue beat(16)3.41%
PT rev (1m)-0.65%
PT rev (3m)-0.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.32%
EPS NY rev (1m)0.44%
EPS NY rev (3m)-21.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.79%
Revenue NY rev (1m)3.32%
Revenue NY rev (3m)12.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80.97
P/FCF N/A
P/OCF N/A
P/B 4.14
P/tB 4.15
EV/EBITDA N/A
EPS(TTM)-3.9
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0.52
BVpS10.27
TBVpS10.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.95%
ROE -34.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.83%
ROA(5y)-28.28%
ROE(3y)-39.23%
ROE(5y)-48.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.22%
Cap/Sales 4.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z 10.96
F-Score4
WACC7.21%
ROIC/WACCN/A
Cap/Depr(3y)270.68%
Cap/Depr(5y)225.81%
Cap/Sales(3y)9.73%
Cap/Sales(5y)8.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-239.53%
EPS Next Y-28.78%
EPS Next 2Y-14.46%
EPS Next 3Y-8.32%
EPS Next 5Y13.67%
Revenue 1Y (TTM)-21.34%
Revenue growth 3Y13.65%
Revenue growth 5Y2.75%
Sales Q2Q%6.7%
Revenue Next Year-21.79%
Revenue Next 2Y10.94%
Revenue Next 3Y20.76%
Revenue Next 5Y58.44%
EBIT growth 1Y-41.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.88%
EBIT Next 3Y-25.36%
EBIT Next 5YN/A
FCF growth 1Y-0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3%
OCF growth 3YN/A
OCF growth 5YN/A